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The Chinese Hypertension Intervention Efficacy Study
(CHIEF) is a multi-centre randomized controlled clinical
trial comparing the effects of amlodipineþangiotensin II
receptor blocker and amlodipineþdiuretics on the
incidence of cardiovascular events, represented as a
composite of non-fatal stroke, non-fatal myocardial
infarction and cardiovascular death events in high-risk
Chinese hypertensive patients. The study also evaluates
the long-term effects of lipid-lowering treatment and
lifestyle modification. From October 2007 to October
2008, 13542 patients were enrolled into the study in 180
centres in China. Patients will be followed up for 4 years.
There was no difference in baseline characteristics
between the two blood pressure arms.
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Introduction
Hypertension is a major cause of morbidity and
mortality, and an important public health challenge
worldwide. Approximately 26.4% of the adult
population worldwide had hypertension in 2000,
and this is expected to increase to 29.2% by 2025.
1
Hypertension accounts for approximately two-thirds
of all strokes and 50% of heart attacks. It causes 7.1
million premature deaths per year and 4.5% of the
global burden of diseases.
2 In China, according to
the 2002 National Nutritional Survey, hypertension
affects 18.8% of the adult population and is a
leading cause of heart disease, stroke and kidney
failure.
3 There are more than 1.5 million new-onset
strokes in China every year.
4 The slope of the
relationship between blood pressure (BP) and stroke
in China and the Asia-Pacific region is steeper than
that in western studies.
5 This means that a better
control of hypertension might have substantial
beneficial effects on the cardiovascular morbidity
and mortality. Many large clinical trials and meta-
analyses
6–10 showed that effective BP control can
significantly reduce cardiovascular morbidity and
mortality. There was a 22% reduction in coronary
heart disease (CHD) events and a 41% reduction in
stroke for a systolic BP reduction of 10mmHg or
diastolic BP reduction of 5mmHg.
10 Therefore, an
important key to reducing the burden of hyper-
tension-related cardiovascular disease (CVD) is to
increase the proportion of patients who achieve
optimal BP control.
Despite the availability of a large number of
antihypertensive agents, the majority of patients
with hypertension do not achieve the recommended
target BP of o140/90mmHg (or o130/80mmHg for
patients with certain comorbid conditions that
increase the risk, that is, diabetes mellitus and
chronic kidney disease) with antihypertensive
monotherapy. The Seventh Report of the Joint
National Committee on Prevention, Detection,
Evaluation and Treatment of High Blood Pressure
(JNC 7)
8 advocates two-drug combinations using
different drug classes in the majority of patients.
Combination therapy with different mechanisms of
actions such as a calcium channel blocker (CCB) and
an angiotensin receptor blocker (ARB) or diuretics
improves the overall efficacy and tolerability. CCBs
are the most widely used antihypertensive drugs in
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conducted in China, such as the Systolic Hypertension
in China Trial (Syst-China),
11 the Shanghai Trial Of
Nifedipine in the Elderly (STONE)
12 and the
Felodipine Event Reduction (FEVER)
13 chose
CCBs as the basic treatment. These agents showed
good efficacy in Chinese hypertensive patients, so a
CCB-based regimen was chosen for this study.
Diuretics, alone or in combination, are widely used
as first-line hypertension treatment in China. Stu-
dies with CCBþdiuretics have shown that this
combination was effective in high-risk patients.
13,14
Use of newer agents such as the angiotensin II
receptor blocker (ARB), telmisartan, can help
avoid some adverse metabolic effects, and may
have additional cardiovascular protective effects.
When telmisartan is used in combination with
amlodipine, it can substantially offset the peripheral
oedema caused by amlodipine.
15 So far, no
large-scale clinical trials have reported on the
effects of the CCB and ARB combination on
cardiovascular events.
Hypertension is often complicated with other risk
factors. Cross-sectional studies have frequently
reported a high prevalence of dyslipidaemia in
hypertensive subjects, which considerably increases
their risk of a future CHD.
16,17 The recent results of
the Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT-LLA)
18 showed that treatment with a
lipid-lowering agent, atorvastatin, in hypertensive
patients reduced CHD and stroke, whereas the
Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT-LLT) study
19
did not show a significan effect of pravastatin on
either all-cause mortality or CHD.
The rationale for the CHIEF study is to try to
intervene the overall risk factors of hypertension,
and answer the following issues related to hyper-
tension management: whether a newer combination
of antihypertensive agents, CCB and ARB, can
produce greater benefits in terms of reducing
cardiovascular events than the combination of CCB
and diuretics; whether lipid lowering with a statin
provides additional beneficial effects in those
hypertensive patients with a high–normal level of
serum total cholesterol. In addition, we would like
to assess the effects of lifestyle modification on the
BP level and cardiovascular outcomes.
Materials and methods
Study Design
The CHIEF study is a large-scale, multi-centre
clinical trial that involves a comparison of two
treatments in a factorial design. Both treatments are
in accordance with the prospective, randomized,
open-labelled, blinded endpoint evaluation (PROBE)
design. This trial was approved by the ethics
committee. This study began in 2007, and the
patients will be followed up for an average of
4 years. More than 13000 hypertension patients
were enrolled from 180 clinical centres in China.
Inclusion and exclusion criteria
Antihypertensive regimen comparison. Hyperten-
sion patients aged 50–79 years were eligible if their
BP was 140–179/90–109mmHg at randomization
after a 2-weeks run-in period. All patients had to
have at least one additional cardiovascular risk
factor, indicated by a history of stroke; myocardial
infarction (MI); stable angina pectoris; underwent
coronary artery angioplasty at least 3 months
earlier; transient ischaemic attack; cardiac insuffi-
ciency (NYHA class II); peripheral vascular disease,
controlled type 2 diabetes; mild or moderate
chronic nephropathy (urine albumin 4300mg per
24h, or blood creatinine 41.5mg per 100ml or
4133mmoll
 1); overweight (body mass index
425kgm
 2), or obesity or abdominal obesity (waist
circumference: male X85cm, female X80cm); ab-
normal blood lipid levels (total cholesterol (TC)
45.7mmoll
 1, high-density lipoprotein (HDL)
o1.0mmoll
 1, triglycerides 41.76mmoll
 1); family
history of premature cardiovascular disease (onset
before 50 years of age); age X65 years; current
cigarette smoker; left ventricular hypertrophy (LVH);
intimal thickening or atherosclerotic plaque in
the carotid arteries; hypertensive fundus oculi grade
III–IV or retinal atherosclerosis grade III–IV.
BP was measured on three visits, 1 week apart, and
mean values were calculated. The diagnosis of arterial
hypertension was based upon elevations of either
systolic (4140mmHg) or diastolic (490mmHg) BP.
Patients with any of the following conditions were
excluded from this study: secondary hypertension;
history of cerebrovascular events or MI within 3
months before registration; severe cardiomyopathy
or significant valvular disease; unstable angina;
severe liver disease or nephropathy (alanine amino-
transferase (ALT) elevation 42 ULN or serum
creatinine 42.5mg per 100ml); malignant tumor;
gout; pregnancy or women not using contraceptives;
uncontrolled diabetes (fasting plasma glucose
410mmoll
 1, despite therapy); known allergies or
contraindications to study drugs; considered to be
unsuitable for participation in the clinical trial
according to the investigator’s opinion.
Lipid-lowering comparison. All subjects were eli-
gible for the antihypertensive regimen comparison,
and their serum cholesterol at screening was 4.0–
6.1mmoll
 1. Patients were excluded if they had
definite and specific indication for, or contraindica-
tion to, treatment with statin, an obvious hepatic
dysfunction or unwillingness to cooperate.
Lifestyle modification. All subjects were eligible
for the antihypertensive regimen comparison.
The investigators obtained written informed con-
sent from the patients before their participation in
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the data directly into an electronic database main-
tained by Dorway.
Run-in period
All previous antihypertensive medication was dis-
continued for 2 weeks, and BP was measured at the
end of the second week of the run-in period. All
patients with a systolic BP (SBP) of 140–179mmHg
and/or a diastolic BP (DBP) of 90–109mmHg were
randomized to treatment. Patients were not enrolled
if they were unable to discontinue their antihyper-
tensive therapy for 2 weeks.
Randomization
Allocation to study treatment was carried out by
internet using a central, computer-based randomiza-
tion service in 2 2 factorial design. All patients
were randomly allocated to amlodipineþcompound
amiloride (amiloride/hydrochlorothiazide; group A)
or amlodipineþtelmisartan (group T). Patients with
serum TC levels between 4.0–6.1mmoll
 1 were
further randomized to statin therapy or a standard
management group. All eligible subjects were ran-
domly assigned to an intensive lifestyle intervention
group or a standard intervention group, according to
the community area where the patients were resident.
Study intervention
Patients were randomized to a combination therapy
with amlodipine 2.5mg per day and half a tablet of
amiloride/hydrochlorothiazide 1.25/12.5mg (group
A) or amlodipine 2.5mg per day and telmisartan
40mg per day (group T). The target BP during the
treatment period was set at o140mmHg systolic
and o90mmHg diastolic, and o130mmHg systolic
and o80mmHg diastolic for diabetes or chronic
kidney disease patients. If the target BP was not
reached at the end of the second week after
randomization, the dose of compound amiloride
was titrated to one tablet per day (amiloride/
hydrochlorothiazide 2.5/25mg) in group A, and
telmisartan was titrated to 80mg per day in group
T. If the target BP was not reached after 4 weeks of
treatment, the dosage of amlodipine in both groups
was increased to 5mg/day (Figure 1). If the BP
remained uncontrolled 2–3 months after randomiza-
tion, other antihypertensive agents including ACE
inhibitor, b-blockers and a-blockers were added at
the discretion of the investigator’s opinion.
Patients with serum TC levels of 4.0–6.1mmoll
 1
were randomized to statin intervention or standard
treatment. Those in the statin treatment group
receive oral simvastatin 10mg per day, whereas
patients receiving standard treatment are managed
at the discretion of their investigator’s opinion.
Adverse effects (for example, myalgia) are recorded
and extra biochemical tests, such as ALT and
creatinine kinase, should be carried out if necessary.
Communities matched by similar socioeconomic
conditions were randomly designated as an active
group and a conventional group with regard to the
strength of the lifestyle intervention. As required by
the 2005 Chinese Hypertension Guidelines,
20 patients
receiving aggressive treatment were educated on a
healthy lifestyle, quarterly in the first year of the study
and biannually in the second year. Lifestyle changes
included a reduction in body weight of p5kg for
obese patients, decreasing salt intake, 30min of
moderate physical activity X3 times per week,
reduction in cigarette smoking or smoking cessation,
limiting alcohol intake or abstinence from alcohol.
Follow-up and measurements
During the screening period, patients were visited
two times at 2 weeks’ interval. Following randomi-
zation, each patient is reviewed at 2 weeks, 1 month,
2 months, 3 months and 3-monthly thereafter until
the final visit.
At each visit BP is measured by a mercury
manometer using a cuff of appropriate size. The
device is calibrated every 6 months. The appearance
of the first Korotkoff sound is taken as SBP, and the
pressure at which the Korotkoff sound disappears
(fifth phase) as DBP. On each visit, sitting BP is
measured three times at 1-min intervals, after the
patient has remained in a seated position for 5min.
The average of the second and third SBP and DBP
measurements is used in the analysis. At the
screening and final visit, a full physical examination
is carried out and blood sample is taken for risk
factors and safety evaluation. Mini-mental state
examination (MMSE) assessment is also conducted
in the first visit, 2-year visit and last visit. The life
quality and lifestyle questionnaire, and hypertension
knowledge questionnaire are completed every year.
Study outcomes
The primary outcomes are the composite of non-
fatal stroke, non-fatal MI and cardiovascular death.
SBP/DBP target: <140/90 mmHg
or <130/80mmHg for diabetes and CKD
A 2.5mg + T 40mg
A 2.5mg + T 80mg
Add other antihypertensive agents
Run-in period
A 2.5mg + D 0.5 tab
A 2.5mg + D 1 tab
Add other antihypertensive agents
A 5mg + D 1 tab
A 5mg + T 80mg
-2W 0 2W 4W 2M 3M 6M 9M
Dosage will be titrated for uncontrolled hypertension
Figure 1 Study design. Abbreviations: A, amlodipine; CKD,
chronic kidney disease; DBP, diastolic blood pressure; D, diuretic
(amiloride 2.5mg and hydrochlorothiazide 25mg per tablet);
M, month; SBP, systolic blood pressure; T, telmisartan; W, week.
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an independent Endpoint Committee blinded to the
study treatment. The secondary outcomes are hos-
pitalization for heart failure, hospitalization for
angina pectoris, coronary revascularization, aortic
dissection, stroke, MI, cardiovascular death, all-
cause mortality, renal insufficiency, tumour, and
new onset of atrial fibrillation and diabetes mellitus.
The BP control rate, change in BP versus baseline,
hypertensive fundus changes, MMSE, quality of life
and lifestyle interventions are also evaluated.
Sample size
The annual incidence of cardiovascular events in
elderly Chinese patients treated with CCB
þdiuretics was reported to be 1.52% in the FEVER
study.
13 If the relative difference in the incidence of
cardiovascular events between the two BP arm
groups is assumed to be 20%, about 6000 patients
are required to achieve a¼0.05 (two sided) and a
power of 85%. On the basis of this calculation, more
than 6000 patients were randomised to each group.
In patients receiving combined antihypertensive
and lipid-lowering therapy, it is assumed that the
incidence of composite cardiovascular events is
1.15% and the relative risk is reduced by 25%.
Statistical analysis
Data will be analysed using the SAS software
package. Continuous data are analysed by two-tailed
unpaired t-test where appropriate. The w
2 test is
used to compare categorical data. Cumulative
incidence was reported by Kaplan–Meier curves
for primary end points. Inter-group comparisons of
cardiovascular events will include group A versus
group B, statin therapy versus standard therapy,
aggressive lifestyle versus conventional lifestyle
interventions, a combination of antihypertensive
þlipid-lowering therapy versus control therapy.
The incidence of LVH, renal dysfunction and
abnormal ambulatory BP, as well as the association
of LVH, renal dysfunction and ambulatory BP with
the rates of cardiovascular events will also be
analysed. A number of subgroup analyses will be
conducted on BP, cardiovascular events and other
variables. Patients’ baseline characteristics, treat-
ment compliance and adverse effects will also be
analysed using descriptive statistics. Difference is
considered significant at Po0.05.
Results
Baseline characteristics of the randomized population
Patient recruitment ended in October 2008, by
which time 13542 patients had been randomized
to the two antihypertensive treatment regimens. Of
these, 9913 patients were further randomized to
lipid-lowering treatment or to the standard manage-
ment group. A total of 180 clinical centres in China
conducted the study. The baseline characteristics of
patients in group A and group Tare given in Table 1.
No significant difference was found between the two
groups.
The average age of recruits was 62 years with 49%
males. The average BP at screening and randomization
Table 1 Baseline characteristics of randomized patients of the blood pressure arm (mean±s.d.)
Group A (n¼6776) Group T (n¼6766)
Sex (number (%) men) 3290 (48.5) 3286 (48.6)
Age (years) 61.5±7.7 61.5±7.7
Body mass index (kgm
 2) 25.9±4.0 26±4.0
Screening SBP (mmHg) 149.5±14.5 149.2±14.2
Screening DBP (mmHg) 89.3±9.7 89.5±9.6
Randomization SBP (mmHg) 157.3±10.8 157±10.7
Randomization DBP (mmHg) 93.1±8.0 93.2±8.0
Anti-hypertensive treatment at screening (number (%)) 6207 (91.6) 6199 (91.6)
Qualifying risk factors or disease
Smoking (number (%)) 1195 (18.5) 1188 (18.4)
Dyslipidaemia 2738 (42.1) 2722 (41.9)
Type 2 diabetes 1143 (17.9) 1209 (19.0)
Mild or moderate nephropathy (number (%)) 76 (1.2) 72 (1.1)
History of stroke 692 (10.8) 677 (10.6)
History of myocardial infarction (number (%)) 155 (2.4) 115(1.8)
History of stable angina pectoris or CHD (number (%)) 849 (12.5) 829 (12.3)
History of cardiac insufficiency (number (%)) 103 (1.6) 102 (1.6)
History of peripheral arterial disease (number (%)) 117 (1.6) 120 (1.9)
History of transient ischaemic attack (number (%)) 668 (10.4) 708 (11.1)
Family history of premature cardiovascular disease (number (%)) 1068 (16.7) 1029 (16.1)
Abbreviations: CHD, coronary heart disease; DBP, diastolic blood pressure; dyslipidaemia, serum cholesterol45.7mmoll
 1 or
HDL-Co1.0mmoll
 1, or triglyceride41.76mmoll
 1; group A, amlodipine+amiloride; group T: amlodipine+telmisartan; SBP, systolic blood
pressure.
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92% patients were taking antihypertensive drugs
before randomization. The history of stroke, history
of CHD, diabetes and dyslipidaemia were 11, 12, 18
and 42%, respectively, reflecting the patient inclusion
criteria for CHIEF.
Discussion
CHIEF randomized in excess of 13000 patients
between October 2007 and October 2008, of whom
73% were recruited into the lipid-lowering limb.
If CHIEF runs its full course, it should report at
the end of 2011. CHIEF will help to define the place
of the two different treatment strategies for the
lowering of BP, both alone and in combination with
lipid-lowering therapy and lifestyle intervention, in
the prevention of cardiovascular outcomes.
The recent guidelines on hypertension
21,22 and on
cardiovascular prevention
23 emphasized that rather
than focus on single-risk factors, focus should be on
the global cardiovascular risk of an individual
patient. The CHIEF study was designed to manage
the hypertensive patients on the basis of an
extensive intervention of the overall risk, including
an initial low dose of combined antihypertensive
therapy, low-dose statin-based lipid-lowering treat-
ment and lifestyle intervention. Extensive interven-
tion of overall risks has great potential to control
hypertension and other cardiovascular risk factors,
to enable more patients to reach their target BP, and
further reduce the risk of cardiovascular events.
There were a number of large-scale randomized
clinical trials involving combination treatment, such
as ACCOMPLISH (Avoiding Cardiovascular events
through COMbination therapy in Patients LIving
with Systolic Hypertension),
24,25 ONTARGET (On-
going Telmisartan Alone and in combination with
Ramipril Global Endpoint Trial)
26 and ASCOT.
27
Except the COLM study, which is ongoing in Japan
and aims to compare the effects of the ARB and CCB
combination with the ARB and diuretics combina-
tion on cardiovascular prevention,
28 no other trials
have reported the effect of the CCB and ARB
combination on cardiovascular events so far.
Dyslipidaemia and hypertension commonly co-
existed,
17 and in the CHIEF study there were about
42% patients who had dyslipidaemia. Dyslipidae-
mia augmented the risk of CVD associated with
hypertension. Lipid-lowering treatment in hyper-
tensive patients could exert additional effects on the
prevention of cardiovascular disease.
16,18,29 The
ASCOT-LLA
29 has shown that treatment with ator-
vastatin for 3 years reduced the incidence of
coronary events and stroke in hypertensive patients
with a serum TC of p6.5mmoll
 1. The investigators
suggested that on the basis of these findings statins
should be considered in all hypertensive patients
despite their cholesterol levels. ASCOT also sug-
gested that the combination of antihypertensive and
lipid-lowering therapy was better than either agent
alone in terms of reducing cardiovascular events.
Williams et al.
22 proposed that the most effective
regimen for reducing cardiovascular risk is the
combination of antihypertensive and lipid-lowering
therapy. In light of these findings, the determination
of which combination of agents is better for
improving outcomes is the focus of current clinical
studies.
Treatment for high BP should be included in life-
style modification. The recommendations for life-
style modification were evidence-based and in-
cluded adoption of a healthy dietary pattern, such
as the Dietary Approaches to Stop Hypertension
(DASH) diet,
30 losing weight if overweight, reducing
sodium intake, increasing physical activity and
limiting alcohol intake. The 2005 Chinese hyperten-
sion guidelines
20 also proposed the same views.
In summary, CHIEF is designed with several
features, which together produce a unique trial.
The CHIEF study is expected to be completed in
2011. We believe that the CHIEF study will provide
useful information regarding antihypertensive ther-
apy in elderly patients. It is hoped that the results of
this study will, on completion, contribute to the
evidence-based practice in the care of hypertensive
patients. This study will prevent CVD, and will
promote BP control rate and good adherence during
long-term treatment. It is expected that the follow-
up rate of patients on randomized treatment will be
X90%, and the BP control rate will be X70%.
Combination therapy is a key treatment strategy, and
the management of patients with hypertension is
moving towards integrated intervention. Antihyper-
tensive treatment should not be based on BP alone;
modification of lipid profile and lifestyle interven-
tions should also be taken into account in the overall
management plan.
There were two limitations of this study. First, the
allocation for lifestyle management comparison was
not randomized but just regionally based; there were
likely to be confounders in influencing the inter-
pretation of differences between groups. Second, the
sample size calculated was mainly focused on the
BP-lowering arm and lipid-lowering arm; the esti-
mated power for lifestyle intervention maybe stati-
stically low.
What is known about topic
K Event rates of cardiovascular disease in China differ from
those in Europe and the United States. The prevalence of
myocardial infarction is lower and that of stroke is higher in
China.
4,5
K The above differences may be partly explained by
differences in the lifestyles of China and Western countries,
which are reflected in the body mass index (BMI).
What this study adds
K The present study shows that the prevalence of stroke and
myocardial infarction in high-risk hypertensive patients in
China is 10.7% and 2.1%, respectively.
K The present study shows that the mean BMI is 26kgm
 2.
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